Home ADNKronos Pharming announces US FDA approval of Joenja® (leniolisib) as the first and only treatment indicated for APDS
 

Immediapress

Pharming announces US FDA approval of Joenja® (leniolisib) as the first and only treatment indicated for APDS

 

(Adnkronos) - APDS (activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome) is a rare and progressive primary immunodeficiency Joenja® is a targeted treatment of APDS for adult and pediatric patients 12 years of age and older Joenja® is expected

I contenuti di VeneziePost sono a pagamento.
Per visualizzare questo articolo e tutti i nostri contenuti scegli tra queste opzioni
Sei già iscritto a VeneziePost?
Clicca qui sotto e inserisci le tue credenziali
Accedi
Facebook Twitter Linkedin Email